Ki-chul W. Sung

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 182 publications

Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging.

Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging.

Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD
Published: April 18, 2026

Age- and Sex-Specific Patterns of Cardio-Ankle Vascular Index in Asymptomatic Adults.

Age- and Sex-Specific Patterns of Cardio-Ankle Vascular Index in Asymptomatic Adults.

Journal: JACC. Asia
Published: April 15, 2026

From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension.

From concept to clinical practice: the evolution of low- and ultra-low-dose triple combination therapy for hypertension.

Journal: Clinical hypertension
Published: March 05, 2026

Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.

Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.

Journal: Hypertension (Dallas, Tex. : 1979)
Published: February 20, 2026

From Children to the Entire Population: Policy Lessons From a Decade of Successful Sodium Intake Reduction in South Korea.

From Children to the Entire Population: Policy Lessons From a Decade of Successful Sodium Intake Reduction in South Korea.

Journal: Korean circulation journal
Published: December 02, 2025

Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.

Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.

Journal: Drug design, development and therapy
Published: November 09, 2025

Burden of metabolic diseases, 1990-2023, with forecasts to 2030 for the Asia-Pacific region.

Burden of metabolic diseases, 1990-2023, with forecasts to 2030 for the Asia-Pacific region.

Journal: Metabolism: clinical and experimental
Published: October 28, 2025

MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome.

MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome.

Journal: Science China. Life sciences
Published: August 27, 2025

Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension.

Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension.

Journal: Journal of the American College of Cardiology
Published: August 04, 2025

Long-term clinical outcome and risk stratification across stages of cardiovascular-kidney-metabolic syndrome in a nationwide cohort.

Long-term clinical outcome and risk stratification across stages of cardiovascular-kidney-metabolic syndrome in a nationwide cohort.

Journal: The Korean journal of internal medicine
Published: June 22, 2025

Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study.

Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study.

Journal: Cardiovascular diabetology
Published: June 22, 2025

Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.

Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.

Journal: Clinical therapeutics
Published: June 15, 2025
Showing 1-12 of 182

Last Updated: 09/26/2026